Forge Biologics' FBX-101, an Innovative AAV Gene Therapy for Krabbe Disease, Granted Innovation Passport Designation in the UK
Wednesday, March 20, 2024
Forge Biologics, a subsidiary of Ajinomoto Bio-Pharma Services focused on genetic medicine, has announced a significant achievement today. The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has granted Innovation Passport designation to their latest AAV gene therapy program, FBX-101. This designation allows entry into the Innovative Licensing and Access Pathway (ILAP), designed to expedite regulatory processes for innovative treatments.
FBX-101 targets Krabbe disease, a rare and typically fatal neurodegenerative condition affecting infants. Dr. Maria Escolar, Forge's Chief Medical Officer, will discuss the significance of this regulatory milestone at the Advanced Therapies Conference 2024 in London, where updated data from the REKLAIM clinical trial will be presented.
Dr. Escolar emphasized the urgency of addressing Krabbe disease due to its rapid progression in young patients. The positive outcomes observed in the REKLAIM trial underscore the potential of FBX-101 in treating this devastating condition.
The REKLAIM trial evaluates FBX-101's safety and efficacy in patients with both infantile and late-onset Krabbe disease. Initial results demonstrate favorable safety profiles and notable improvements in motor function among treated patients.
FBX-101 has received Orphan Drug and Priority Drug designations from the European Medicines Agency (EMA) and Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA), reflecting its potential as a leading gene therapy for Krabbe disease worldwide.
ILAP aims to streamline regulatory processes in the UK for therapies addressing critical medical needs, facilitating faster patient access. This designation also enhances Forge's global regulatory experience, positioning them to provide comprehensive support to customers utilizing their services.
Krabbe disease is a rare genetic disorder caused by mutations in the GALC gene, leading to toxic buildup of psychosine in nerve cells and subsequent neurodegeneration. FBX-101 delivers a functional copy of the GALC gene via an adeno-associated viral vector, potentially addressing both central and peripheral neuropathy associated with the disease.
Overall, this regulatory milestone represents a significant step forward in the development of FBX-101 and offers hope to patients and families affected by Krabbe disease.
Source: businesswire.com
